SS
KROS icon

SBI Securities’s Keros Therapeutics KROS Stock Holding History

SBI Securities’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21 Hold
2
– – ﹤0.01% 3836
2026
Q1 		$22 Hold
2
– – ﹤0.01% 3742
2025
Q4 		$41 Sell
2
-781
-100% -$13.7K ﹤0.01% 3620
2025
Q3 		$12.4K Buy
783
+161
+26% +$2.38K ﹤0.01% 1666
2025
Q2 		$8.3K Buy
622
+600
+2,727% +$8.1K ﹤0.01% 1784
2025
Q1 		$224 Buy
22
+20
+1,000% +$232 ﹤0.01% 3188
2024
Q4 		$32 Buy
+2
New +$104 ﹤0.01% 3728

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

SBI Securities's KROS Position: Q2 2026 in Review

SBI Securities held its Keros Therapeutics (KROS) position steady in Q2 2026 at 2 shares worth $21. The position accounts for ﹤0.01% of the portfolio, ranked #3836.

SBI Securities first reported a position in KROS in Q4 2024 and has held it in 7 quarters since. The position peaked at $12.4K in Q3 2025. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • SBI Securities held 2 shares of Keros Therapeutics worth $21 as of Q2 2026.
  • SBI Securities left its Keros Therapeutics share count unchanged in Q2 2026.
  • Keros Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3836 holding.
  • SBI Securities first reported a position in Keros Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's Keros Therapeutics position peaked at $12.4K in Q3 2025.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.